Table 1.

Characteristics of the Patients at Baseline.^*

Characteristic	Patients (N = 126)
Median age (range) — yr	63.5 (37–80)
Female sex — no. (%)	63 (50.0)
Race — no. (%)†
White	103 (81.7)
Asian	19 (15.1)
Black	2 (1.6)
Other	2 (1.6)
Smoking history — no. (%)
Never smoked	6 (4.8)
Current smoker	15 (11.9)
Former smoker	102 (81.0)
Missing data	3 (2.4)
ECOG performance-status score — no. (%)‡
0	38 (30.2)
1	88 (69.8)
Brain metastasis — no. (%)
Yes	26 (20.6)
No	100 (79.4)
Histologic subtype — no. (%)
Squamous-cell carcinoma	1 (0.8)
Adenocarcinoma	120 (95.2)
Large-cell carcinoma	3 (2.4)
Bronchoalveolar carcinoma	2 (1.6)
Metastatic disease — no. (%)
Yes	122 (96.8)
No	4 (3.2)
No. of previous lines of anticancer systemic therapy — no. (%)
1	54 (42.9)
2	44 (34.9)
3	28 (22.2)
Type of previous systemic anticancer therapy — no. (%)
Chemotherapy§	115 (91.3)
Platinum-based chemotherapy	113 (89.7)
Checkpoint inhibitor	116 (92.1)
Anti–PD-1 or anti–PD-L1 agent	115 (91.3)
Platinum-based chemotherapy and PD-1 or PD-L1 inhibitor	102 (81.0)
Antiangiogenic monoclonal antibodies	25 (19.8)
Targeted small molecules¶	9 (7.1)
Other║	1 (0.8)

^*P ercentages may not total 100 because of rounding. PD-1 denotes programmed death 1, and PD-L1 programmed death ligand 1.

^†R ace was reported by the patient.

^‡P erformance-status scores on the Eastern Cooperative Oncology Group (ECOG) scale range from 0 to 5, with higher numbers in§dicating greater disability.

^§T wo patients who did not receive platinum-based chemotherapy received pemetrexed, docetaxel, gemcitabine, and vinorelbine.

^¶Targeted small molecules included capmatinib, nintedanib, trametinib, vorolanib, RMC-4630, sitravatinib, and cobimetinib.

^║The other previous anticancer systemic therapy was an investigational agent.